{
  "docId": "019dd923-622c-750b-8b99-bca3fd68622d",
  "docSlug": "4c8fe6013c68",
  "documentTitle": "iRhythm Technologies, Inc. (IRTC)",
  "authorId": "54_Spruce_Point_Capital",
  "authorName": "Spruce Point Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-18 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 43,
  "pageCount": 101,
  "prevPage": 42,
  "nextPage": 44,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "Uses a quote from an earnings call to frame a 'villain' narrative regarding regulatory compliance.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "callout_box",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b99-bca3fd68622d/43",
  "deckHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d#slide-43",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "We believe the implications for iRhythm’s historical compliance are huge.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-0395-748f-9568-ddcbf8a7263d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.32,
        "w": 0.96,
        "x": 0.02,
        "y": 0.61
      },
      "kind": "paragraph",
      "text": "We are troubled by Blackford's framing of the issue. The FDA clearly identified life-threatening issues with iRhythm's post-wear results analysis, that CCTs were misreading arrhythmia data. However, because iRhythm did not view these activities as part of its “product”, Blackford characterized the Form 483 as not related to product safety. Blackford failed to communicate that the FDA clearly viewed the issues it identified as related to product safety. Viewed another way, iRhythm effectively ignored 4,000 complaints that, among other things, called into question the accuracy of the data it was providing to physicians. Blackford has repeatedly stated or implied that the FDA is trying to “figure out” how it wants to regulate products in the MCT market. The FDA seems to know exactly how it wants to regulate them: the way that best ensures patient safety. That just happens to be inconsistent with the way iRhythm was apparently managing its business. We believe this issue opened an enormous can of worms, as Blackford effectively admitted that iRhythm had not viewed these activities as subject to the same regulatory oversight as the FDA did. This is particularly troubling in light of the various other operational issues that have surfaced around these operations.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13d66966-50a5-4481-9e14-9d142a5145b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.96,
        "x": 0.02,
        "y": 0.17
      },
      "kind": "paragraph",
      "text": "On the Company’s Q2 2024 earnings call during which it first disclosed the receipt of additional Form 483s, CEO Blackford disclosed a core disagreement between iRhythm and the FDA: whether or not the post-wear results analysis and the CCTs who perform/validate that work are “part of the product” being offered. We believe the implications for iRhythm’s historical compliance are huge.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "674da67f-c4ec-4904-ad67-01ee706d0faa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.73,
        "x": 0.25,
        "y": 0.35
      },
      "kind": "quote",
      "text": "…I think the fundamental issue sort of comes down to whether the IDTF, the CCTs, if you will, the clinical technicians, are they part of the product or are they not? And I think from the beginning of time, we view those as separate items. And I think the FDA has a bit of a different perspective right now that we're working through. But when you start to think about those 2 things differently, meaning ourselves versus how the FDA may be looking at it, you start to land in different places, when it comes to complaint handling or reporting or process controls and how you document those controls or how you go about your statistical techniques. I think it's important to note, like, there is no conversations in here with the FDA in the course of these inspections around the overall safety or efficacy of our product.",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99a2abb0-5a58-42c5-ab7b-fcab01bf4d9d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“...I think the fundamental issue sort of comes down to whether the IDTF, the CCTs, if you will, the clinical technicians, are they part of the product or are they not? And I think from the beginning of time, we view those as separate items. And I think the FDA has a bit of a different perspective right now that we're working through.” — iRhythm CEO Blackford on Q2 2024 Earnings Call, 8/1/24",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-0395-748f-9568-e2dc39ea2a61",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.25,
        "x": 0.02,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "Source: iRhythm Q2 2024 earnings call transcript",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b3a8e248-96a6-4479-8f59-568d581bb20b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.65,
        "x": 0.31,
        "y": 0.03
      },
      "kind": "title",
      "text": "iRhythm Used Its Own Definition Of Its “Product” To Understate Patient Safety Issues To Investors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97d66156-aa67-4407-918a-098547931c69",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "ceo-quote-contradiction",
      "slug": null,
      "matchId": "bf56cf4d-8c84-4121-b204-82f84b352bb4",
      "evidence": "Contrasting CEO statement with activist interpretation of FDA findings",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 57,
      "from": 41,
      "beatId": "03d3d92f-7e30-44d5-bc2e-ebe3067ddf10",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "Problem Statement",
      "beatSlug": null,
      "evidence": "The document outlines various problems with iRhythm's business strategy and growth prospects.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}